There’s no better due diligence in the psychoactive drug space than Health Canada. Loads of pharma companies have investor decks that promise they’ll one day be in the psychedelics…
DMT
Algernon Pharmaceuticals (AGN.C) filed a combined clinical trials of investigational medicinal products and ethics approval application with the United Kingdom Medicines and Healthcare Products Regulatory Agency for its planned…
The world’s first psychedelic ETF, PSYK, is an industry bellwether which indicates the psychedelics space continues to take a drubbing since the ETF launched in January. The fund closed…
Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine…
Mindset Pharma (MSET.C) announced they have filed a new patent with the US Patent and Trade Office (USPTO), extending its Family 4 compounds, a set of novel DMT/5-MeO-DMT analogs….
Filament Health (FH.NEO) announced today that it has been granted an amendment to its existing Health Canada Dealer’s License, bolstering the Company’s position at the forefront of natural psychedelic…
MindMed (MMED.NE, MNMD.Q) announced the start of a Phase 1 trial to assess the safety, pharmacokinetics and pharmacodynamics of DMT. DMT, properly known as N,N-Dimethyltryptamine is a psychoactive chemical…
Core One Labs’ (COOL.C) wholly-owned subsidiary, Akome Biotech, has begun the development of a next-generation psychedelic drug formulation for the purpose of mitigating neurological damage that results from ischemic…
Core One Labs (COOL.C) has completed the acquisition of Akome Biotech, a psychedelic-based pharmaceuticals company focused on providing effective and safe solutions to patients suffering from stroke and neurological…
Pharmadrug’s (BUZZ.C) subsidiary Sairiyo Therapeutics received their orphan drug designation (ODD) for dimethyltryptamine (DMT) from the United States Food and Drug Administration (FDA) for the prevention of ischemia-reperfusion injury…